Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 219

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 219
---
 7, 2018, the parties entered into a first amendment to the exclusive license agreement, and on July 10,
2019, the parties entered into a second amendment to the license agreement.

On January 11, 2019, Acticule
and Versitech Limited entered into a second license agreement for ALS-4, where Acticule exclusively licensed the intellectual property
rights on certain HKU-owned improvements to the original licensed invention.

Under the exclusive license
agreements, we were granted an exclusive, royalty-bearing, sublicensable licenses to develop, make, have made, use, sell, offer for sale
and import products that are covered by the licensed patents (as described below). The territory of the licenses is worldwide and the
field of the licenses is for treatment or prevention of bacterial infections caused by Staphylococcus aureus including MRSA and bacterial
virulence.

We paid an upfront fee upon
entering into the license agreements. We are required to pay less than 10% of the net sales of the licensed products sold by us or our
affiliates as royalties, as well as a low teens percentage of sublicense royalties that we receive from our sublicensees, if any. In addition,
we agreed to pay to the licensor aggregate regulatory milestones of up to US$1 million subject to the following achievements: submission
of investigational new drug application; completion of phase 1, 2 and 3 clinical trials; and submission of new drug application; grant
of regulatory approval. We also agreed to pay to the licensor aggregate sales milestones of up to US$7.8 million subject to the following
achievement: first commercial sale; and annual net sales exceeding US$100 million in one jurisdiction.

Pursuant to the license agreements,
Acticule became the exclusive licensee of 2 pending U.S. non-provisional patent applications and 2 PCT applications (now expired).
Prior to the expiration of the PCT applications, we filed national phase applications in member states of the EPO, in PRC and 12 other
jurisdictions. The claimed inventions are described as: “Compounds Affecting Pigment Production and Methods for Treatment of Bacterial
Diseases.”

Acticule has the right to grant
sublicenses to third parties under the license agreements without prior approval from Versitech Limited and to assign the agreements to
any successor to the business related to the licenses. In the event that Acticule makes an improvement to